Clinical Hemorheology and Microcirculation - Volume 10, issue 6
Purchase individual online access for 1 year to this journal.
Price: EUR 185.00
Impact Factor 2021: 2.375
Clinical Hemorheology and Microcirculation, a peer-reviewed international scientific journal, serves as an aid to understanding the flow properties of blood and the relationship to normal and abnormal physiology. The rapidly expanding science of hemorheology concerns blood, its components and the blood vessels with which blood interacts. It includes perihemorheology, i.e., the rheology of fluid and structures in the perivascular and interstitial spaces as well as the lymphatic system. The clinical aspects include pathogenesis, symptomatology and diagnostic methods, and the fields of prophylaxis and therapy in all branches of medicine and surgery, pharmacology and drug research.
The endeavour of the Editors-in-Chief and publishers of
Clinical Hemorheology and Microcirculation is to bring together contributions from those working in various fields related to blood flow all over the world. The editors of
Clinical Hemorheology and Microcirculation are from those countries in Europe, Asia, Australia and America where appreciable work in clinical hemorheology and microcirculation is being carried out. Each editor takes responsibility to decide on the acceptance of a manuscript. He is required to have the manuscript appraised by two referees and may be one of them himself. The executive editorial office, to which the manuscripts have been submitted, is responsible for rapid handling of the reviewing process.
Clinical Hemorheology and Microcirculation accepts original papers, brief communications, mini-reports and letters to the Editors-in-Chief. Review articles, providing general views and new insights into related subjects, are regularly invited by the Editors-in-Chief. Proceedings of international and national conferences on clinical hemorheology (in original form or as abstracts) complete the range of editorial features.
The following professionals and institutions will benefit most from subscribing to
Clinical Hemorheology and Microcirculation: medical practitioners in all fields including hematology, cardiology, geriatrics, angiology, surgery, obstetrics and gynecology, ophthalmology, otology, and neurology. Pharmacologists, clinical laboratories, blood transfusion centres, manufacturing firms producing diagnostic instruments, and the pharmaceutical industry will also benefit.
Important new topics will increasingly claim more pages of
Clinical Hemorheology and Microcirculation: the role of hemorheological and microcirculatory disturbances for epidemiology and prognosis, in particular regarding cardiovascular disorders, as well as its significance in the field of geriatrics. Authors and readers are invited to contact the editors for specific information or to make suggestions.
Abstract: We compared the effect of a constant versus a decreasing ultrafiltration rate during hemodialysis on plasma viscosity, erythrocyte aggregation (hematocrit adjusted to 40%) and blood viscosity (hematocrit 40%; shear rates 23.04, 46.08, 115.2 and 230.4/″) in 5 woman and 10 men with chronic renal failure due to different origins, mean age 67.3 ± 6.7 years. Measurements were done before and after dialysis. The regimen with a constant ultrafiltration rate increased plasma viscosity (1.36 ± 0.09 to 1.48 ± 0.16 cPs, P < 0.01) and blood viscosity at high shear (230.4/″; 3.51 ± 0.34 to 3.91 ± 0.73 cPs, p <…0.05), the other parameters remained unchanged. There was a good correlation to the change in protein concentration before and after dialysis due to hemoconcentration (6.61 ± 0.54 to 7.51 ± 1.02 mg%, r = 0.85, p < 0.01). The regimen with a decreasing ultrafiltration rate caused no significant change in the rheological parameters. The weight loss was comparable in both regimens. We conclude that a decreasing ultrafiltration rate during hemodialysis is associated with less disturbances of rheology.
Abstract: The possible influence of dialysis on the metabolism of reactive oxygen species as well as the flow properties of blood were investigated. 22 patients suffering from chronical renal failure were hemodialysed every second day. 11 of them were additional treated with ultraviolet irradiated own blood. The concentration of thiobarbituric acid reactive substances (TBARS) was normal (3.6±0.8 nmol) before hemodialysis and rose during hemodialysis up to 4.6±1.0 nmol). This increase of TBARS was no longer seen in the uv treated patients. The parameters of RBC aggregation were neither significantly different in the two patient groups before the treatment nor different in…comparison with healthy persons. The orientability of RBC of the patient groups was significantly reduced in comparison with that of the healthy group at the beginning of investigation and was significantly improved after uv treatment. The retransfusion of uv irradiated own blood seems to result in a decreased oxidative stress.
Abstract: The deformability of RBC in uremic hemodialysed children was determined by two different micropipette techniques (apparent elastic shear modulus of RBC membrane µ; entry time te and amplitude A) in dependence on the period of rhEPO administration. At the outset, mean hematocrit of the 10 children enclosed in the study was 0.20 +/− 0.02, mean predialysis levels of serum creatinine and urea nitrogen were (919 +/− 163)µMol/l and (24.3 +/− 3.0)mMol/l, respectively. Dialysis was performed with hollow fiber dialyzer three times a week for 4 hours each. Mean µ, te and A in children with end-stage renal disease…were found to be elevated by 126, 54 and 65 %, respectively, above corresponding mean values of the healthy reference group. Under the therapy with rhEPO mean values of µ, te and A were already significantly decreased by 67, 35 and 34 %, respectively, within the correction period (rhEPO dose: 100 IU/kg/week). In the maintenance period of rhEPO therapy (Hct = 0.30 +/− 0.03) the mean values of deformability parameters reached those of the healthy reference group. Mean cell volume of uremic erythrocytes rose significantly under rhEPO administration. This study showed that under rhEPO therapy apart from the desired correction of anemia of end-stage renal disease the impaired rheological properties of uremic RBC will also be normalised. This findings underline that the impaired RBC deformability in hemodialysed uremic patients cannot be attributed to “uremic toxines” alone.